One meta-analysis of 13 observational studies of visfatin and overweight/obese patients involving 644 subjects showed that plasma visfatin concentrations were higher in persons who were overweight/obese, with DM2, metabolic syndrome, and cardiovascular disease [96]. Here, NAMPT is linked to myotonic dystrophy type 2.